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Hepatitis C virus (HCV) is one of the most important pathogens
causing liver-related morbidity and mortality (Alter, 1997). There is no
therapeutic or prophylactic vaccine available for HCV and type I
interferons have been the mainstay of HCV therapeutics (Hoofnagle
and di Bisceglie, 1997). Antiviral therapeutic options against HCV are
limited and yield unsatisfactory responses (Fried et al., 2002). Given
these situations, gaining a detailed understanding of the molecular
mechanisms of interferon resistance has been a high priority in
academia and industry.
Molecular studies of HCV have been hampered by the lack of efﬁcient
in vitroand in vivomodels of infection,whichhasbeenpartlyovercomeby
the development of HCV subgenomic replicons (Blight et al., 2000; Kato
et al., 2003; Lohmann et al., 1999) and the HCV-JFH1 cell culture system(Wakita et al., 2005). HCV-JFH1 is an isolate of HCV genotype 2a that was
obtained from a patient with fulminant hepatitis C. The full-length JFH1
genome has been shown to produce infectious particles in cell culture.
Simultaneously, a robustly replicating intragenotypic chimera has been
reported,which consists of the structural regionof a genotype2a, J6-clone
and nonstructural region of JFH-1 (Lindenbach et al., 2005).
HCV isolates are classiﬁed into seven major genotypes and multiple
subtypes (Gottwein et al., 2009). In infected individuals, HCV exists as
quasispecies of closely related genomes (Bukh et al., 1995). A number of
studies have suggested that the outcome of HCV infection, aswell as the
response to interferon treatment, depends on the genotype or
quasispecies with which the patient is infected. However, it is not
clear how these subtle genetic differences of HCV affect viral replication,
infectivity and host responses. Thus, it is important to establishmultiple
cell culture-permissive strains of different genotypes and isolates of the
same genotype for their potential value for characterizing the virus life
cycle, drug sensitivity and virus-related cell signaling.
Our present work describes the generation of chimeric viruses
with their structural regions from genotype 2b and non-structural
genes from the HCV-JFH1 strain. The intergenotypic 2b/JFH1 viruses
were compared in terms of intracellular replication, infectious virus
production and sensitivity to interferon-alpha. Here we show that the
differences in sensitivity to interferon are attributable to upregulated
expression of the cellular interferon signal attenuator, SOCS3, and that
this upregulation is caused by overexpression of interleukin-6 (IL-6).
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In vitro and in vivo infectivity analyses of HCV-2b and 2b/JFH1
intragenotypic chimeras
First, we investigated the infectivity of the full-length genotype 2b
clone in vitro and in vivo. The full-length genotype 2b HCV clone was
infectious after direct injection of RNA transcribed in vitro into the
livers of human hepatocyte engrafted albumin-uPA/SCID mice (see
the Supplementary Fig. 1). However, transfection of the HCV RNA into
Huh7.5.1 cells did not lead to replication or secretion of virions.
Knowing that the full-length genotype 2b HCV was not infectious in
vitro, we constructed genotype2b/JFH1 intergenotypic recombinants.
We constructed three recombinant clones of 2b/JFH1 (Fig. 1A), which
were joined between E2 and p7 (JE31F), NS2 and NS3 (JE39F), and
within NS2 at nt. 2867 (JEC3F). After transfection of these chimeric
HCV RNAs and JFH-1 RNAs into Huh7.5.1 cells, all four clones
expressed detectable amounts of HCV core protein in the cells
(Fig. 1B) and culture ﬂuid (Fig. 1C). Among the four clones, JEC3F
produced the highest level of core protein in the cells and culture
ﬂuid. Similarly, in the reinfection assays, JEC3F infected naïve cells
most efﬁciently (Figs. 1D and E). We then compared the infectivity of
JEC3F with the other chimeric viruses, genotype2a J6/JFH1 and the
JFH1 clone (Supplementary Fig. 2). Transfection of the individual
clones into Huh7.5.1 cells showed that JEC3F and the 2b/JFH1 chimera
secreted core protein into the medium most efﬁciently (Fig. 1C). We
measured HCV core antigen and HCV-RNA levels in culture superna-
tant of JEC3F and JFH-1 infected cells. As shown in Fig. 1F, the ratio
between supernatant HCV core antigen and HCV-RNA between JEC3F
and JFH1 was well correlated each other.
Comparisons of sensitivity to IFN between intragenotypic chimeras and
JFH1
Next, we investigated the interferon-alpha sensitivity of the three
2b/JFH1 chimeric viruses with different junctions, JE31F, JE39F and
JEC3F, as well as JFH1. The four viral RNAs were transfected separately
into Huh7.5.1 cells and were treated with 0, 1, 3 or 9 IU/mL of
interferon-alpha-2b. Seventy-two hours after addition of interferon,
core antigen was measured in the culture ﬂuid. As shown in Fig. 2, all
2b/JFH1 chimeric clones showed signiﬁcantly higher responses to
interferon than JFH1 (pb0.01). These results indicate that the relative
interferon sensitivity of 2b/JFH1 clones over JFH1 could be attribut-
able to the sequences of HCV-2b-derived structural proteins,
especially core, E1 or E2 protein.
Expression of IFN stimulated genes and STAT1 and 2 phosphorylation in
HCV-infected cells
Knowing that the 2b/JFH1 chimeric clones are more sensitive to
interferon than JFH1, we next analyzed the effects on cellular
interferon signaling. We investigated the expression levels of the
interferon-stimulated genes (ISGs), 25OAS and MxA mRNAs that
mediate antiviral effects (Itsui et al., 2009; Itsui et al., 2006). Induction
of 25OAS and MxA by IFN was signiﬁcantly suppressed in cells
infected with HCV-JFH1 and the JEC3F clones. Of note was that the
induction of these ISGs was suppressed substantially in JFH1-infected
cells compared to JEC3F-infected cells (Figs. 3A and B). We then
detected IFN-induced phosphorylation of STAT1 and STAT2 to pSTAT1
and pSTAT2 in uninfected and JFH1- and JEC3F-infected cells.
Phosphorylation of STAT1 and STAT2 occurs within minutes after
addition of IFN and substantially decreased at time points later than
8 hours {Itsui, 2006 #1025}. Thus, we detected pSTAT1 and pSTAT2
before and at 15 minutes after IFN treatment. As shown in Figs. 3C and
D, production of pSTAT1 and pSTAT2 was decreased substantially in
JFH1-infected cells, compared with uninfected and JEC3F-infectedcells. These ﬁnding indicated that the differences in sensitivity to
interferon of JFH1 and JEC3F were closely associated with attenuation
of the cellular IFN signaling pathway.
SOCS 3 is up-regulated in JFH-infected, IFN-resistant cells
We next investigated the effects of HCV replication on the
expression of SOCS1 and SOCS3 that suppress IFN receptor-mediated
signaling (Song and Shuai, 1998; Vlotides et al., 2004). While SOCS1
mRNA expression did not differ signiﬁcantly between uninfected and
JFH1- and JEC3F-infected cells, the SOCS3 mRNA expression level was
signiﬁcantly higher in JFH1-infected cells than in uninfected and
JEC3F-infected cells (Figs. 4A and B).
Knock down of the SOCS3 gene
To verify that SOCS3 was the key molecule determining the
sensitivity to IFN, we performed siRNA knock down of SOCS3 in the
virus-infected cells. A SOCS3-directed siRNA was cotransfected with
HCV-JFH1 or -JEC3F RNA into Huh7.5.1 cells. Three days after
transfection we measured SOCS3 mRNA expression in JFH1 and
JEC3F-transfected cells with or without SOCS3-siRNA. Interestingly,
SOCS3-knock down in JFH1-transfected cells restored sensitivity of
IFN to the same levels as JEC3F-transfected cells (Figs. 5A and B).
Interleukin-6 is involved in SOCS-mediated interferon resistance
It has been reported that SOCS3 is induced principally by
phosphorylated STAT3 (pSTAT3) (Hanada et al., 2003) and that
interleukin-6 (IL-6) is a strong inducer of pSTAT3 via receptor-mediated
Janus kinase activation in the liver (Ramadori and Christ, 1999). This
background led us to investigate whether overexpression of SOCS3 is
associatedwithoverproductionof IL-6.We investigatedPhosphorylated
STAT3 (pSTAT3) expression and IL-6 mRNA expression in JFH1- and
JEC3F-transfected Huh7.5.1 cells. Phosphorylated STAT3 level was
signiﬁcantly higher in JFH1-transfected cells than JEC3F-transfected
cells and naïve Huh7.5.1cell (Fig. 6A). Moreover IL-6 gene expression
level was signiﬁcantly higher in JFH1-transfected cells than JEC3F-
transfected cells (Fig. 6B). Consistent with previous reports, treatment
of the Huh7.5.1 cells with IL-6 induced expression of SOCS3 and SOCS1
mRNAs with SOCS3 being much stronger than SOCS1 (Fig. 6C).
Anti-IL-6 antibody restored IFN-resistance to HCV-infected cells
To investigate whether IL-6 is responsible for HCV infection-
induced upregulation of SOCS and for resistance to interferon, JFH1
and JEC3F-infected Huh7.5.1 cells were pretreated with antibodies
directed against IL-6 and subsequently treated with interferon.
Interestingly, anti-IL-6-treated HCV-infected cells became signiﬁ-
cantly more susceptible to IFN treatment (Fig. 6D) without
affecting viral expression levels in the absence of interferon
(Fig. 6E). Cellular levels of SOCS3 mRNA were signiﬁcantly lower
in anti-IL-6-treated cells than untreated cells (Fig. 6F). These
results strongly suggested that the interferon resistance of HCV-
infected cells and the difference between the two viral strains are
partly mediated by internal overproduction of IL-6 and subsequent
upregulation of SOCS3.
Determination of the HCV structural region that induced SOCS3 and IL6
We studied further which part of HCV structural polyprotein is
responsible for the difference in interferon-sensitivity. We con-
structed two additional chimeric clones between HCV-2b and JFH1.
The 2bCoreJFH1 had the 2b-core region followed by the JFH1-
structural and nonstructural regions. JCoreC3F was derived from
JEC3F by exchanging the 2b-core with the JFH1-core (Fig. 7A). As
82 G. Suda et al. / Virology 407 (2010) 80–90
83G. Suda et al. / Virology 407 (2010) 80–90shown in Fig. 7B JFH1 and JCoreC3F, which had a JFH1-derived core
region, were signiﬁcantly more resistant to IFN than JEC3F and
2bCoreJFH1, with a 2b-derived core (Fig. 7B). Consistent with the
interferon sensitivity results, JFH1 and JcoreC3F-infected cells
expressed SOCS3 and IL6 mRNAs at signiﬁcantly higher levels
than JEC3F and 2bCoreJFH1-infected cells (Figs. 7C and D). These
differences in gene expression were inversely associated with the
cellular expression levels of each HCV chimeric clone (Fig. 7E).
These results indicate that the amino acid sequence of the core
protein is responsible for IL-6 and SOCS3-medited interferon
resistance.Fig. 2. Comparison IFN-alpha sensitivity among 2b/JFH1 chimeric viruses and JFH1. Ten
μg of JE31F, JE39F, JEC3F, JFH1 RNA were transfected into 5×106 Huh7.5.1 cells. The
transfected cells were divided into 12 wells. Forty eight hours after transfection, cells
were washed twice with PBS and treated with 0, 1, 3 and, 9 U/ml IFN-alpha-2b.
Seventy-two hours after IFN-alpha 2b addition, quantiﬁcation of HCV core antigen in
culture ﬂuids was conducted. The experiments were conducted twice by using Huh 751
cells of different passage, and a representative data was shown. Assays were done in
triplicate and the data are shown as mean±sd. Asterisks indicate p-values of less than
0.05.Discussion
In this study, we succeeded in establishing a new genotype 2b
infectious HCV clone and genotype 2b/JFH1 cell culture-competent
intragenotypic chimeric viruses (Fig. 1). Relative interferon sensitiv-
ities of 2b/JFH1 chimeras, compared with HCV-JFH1 virus (Fig. 2), led
us to conduct a series of assays to investigate the molecular
mechanisms of IFN-related response pathways. We found that IFN-
alpha receptor-mediated cellular responses were more attenuated in
HCV-JFH1- and 2b/JFH1 chimera-infected than in uninfected
Huh7.5.1 cells, but more potently for HCV-JFH1. Precise intragenoty-
pic recombination analyses showed that the amino acid sequence of
the HCV core protein is responsible for the differences in interferon
sensitivity (Figs. 2, 7). The differences in the interferon-mediated
antiviral effects were demonstrated further by the different rates of
induction of interferon-inducible MxA and 25-OAS mRNAs (Figs. 3A
and B) and IFN induced phosphorylation of STAT1 and STAT2 (Figs. 3D
and E). We have demonstrated further that the expression of an
interferon signal attenuator, SOCS3, was signiﬁcantly higher in JFH1
than in 2b/JFH1-infected cells (Song and Shuai, 1998; Vlotides et al.,
2004). Indeed, the siRNA-knock down of SOCS3 in JFH1 and 2b/JFH1-
infected cells resulted in responsiveness to IFN (Fig. 5). Moreover,
cellular expression of IL-6, which increases cytoplasmic phospho-
STAT3 (Fig. 6A) and induces SOCS3 expression (Ramadori and Christ,
1999) was signiﬁcantly higher in JFH1 transfected cells (Fig. 6B).
Furthermore, by pre-treatment with anti-IL-6 antibody, JFH1- and 2b/
JFH1-infected cells partially recovered elevation of SOCS3 expression
and unresponsiveness to IFN (Fig. 6D). Taking all these things
together, it is strongly suggested that the differences in IFN sensitivity
between genotypes or isolates could be explained by SOCS3-mediated
attenuation of interferon responses and, more importantly, IL-6 may
constitute a molecular target to reverse such cellular interferon
resistance.
Vast numbers of studies have failed to construct infectious HCV
clones, other than HCV-JFH1. Murayama, et al. have conducted
intragenotypic homologous recombination analyses between HCV-J6
and –JFH1 and have reported that that the NS3 protease and NS5B
polymerase are essential for replication of the recombinant virus
(Murayama et al., 2007). Up to now, several JFH1-based chimeric
viruses have been reported, which include genotypes 4a (Scheel et al.,Fig. 1. Replication and infection competency of HCV-2b/JFH1 chimeric viruses A. Genomic str
recombination was conducted between the HCV-2b and JFH1 (2a) clones and three chimeric
nt2541 (JE31F) and NS2 at nt. 2867 (JEC3F). B. Immunocytochemistry of HCV core. HCV
Immunocytochemistry was performed 4 days after transfection using mouse-anti-core ant
In vitro transcribed HCV RNAs were transfected into Huh7.5.1 cells by electroporation and
antigen levels were measured. The experiment was done three times with similar results in
HCV RNA-infected Huh7.5.1 cells using Panel B supernatant that have same amount of HCV c
was performed 4 days after infection using mouse-anti-core antibody(green) and DAPI(blue)
of 2b/JFH1 infected cells. JE31F, JE39F, JEC3F RNA-transfected cell culture ﬂuids were used to
Quantiﬁcation of HCV core antigen in culture supernatants was carried out at 24 hours, 48 h
with similar results independently. Panel E shows representative date. F. Comparison betwee
JEC3F RNA transfection, culture supernatant was harvested and subjected to both HCV core
data are shown as mean±sd.2008), genotype 1a, 1b, 2a (Pietschmann et al., 2006), genotype 3a
(Gottwein et al., 2007), genotype 5 a (Jensen et al., 2008) and,
genotype 2b, 6a, 7a (Gottwein et al., 2009). Gottwein, et al.
constructed intergenotypic chimeric HCV from JFH1 and genotypes
1 through 7 and analyzed differences in sensitivity to antiviral drugs
(Gottwein et al., 2009). However, intergenotypic differences in
sensitivity to IFN-alpha and the molecular mechanisms involved
have not been well characterized. In this study, we constructed
several chimeric virus clones between HCV-2b and HCV-JFH1 (2a),
which showed variable sensitivity to IFN and conﬁrmed that the core
region is responsible for such IFN sensitivity. This study may support
the feasibility of such inter and intragenotypic homologous recom-
bination approaches to characterize differences in viral kinetics and
drug responses.
Type I IFNs and their responsive ISGs are the principal mediators of
host defense against virus infections, including HCV (Chang et al.,
1991; Kalvakolanu, 2003; Ronni et al., 1998). On binding of IFNs to
their receptors, IFNAR1 and IFNAR2, Janus kinases-1 and -2 phos-
phorylate STAT1 and STAT2 to form ISGF-3, which translocates to the
nucleus and activates transcription of ISGs (Samuel, 2001; Taniguchi
et al., 2001; Taniguchi and Takaoka, 2002). Members of the SOCS
family are potent inhibitors of type I and type III IFN-induced
activation of the Jak–STAT pathway and subsequent expression of
ISGs (Vlotides et al., 2004). In HCV subgenomic replicon-expressing
cells, expression levels of SOCS3 were inversely correlated with
sensitivity to IFN to suppress viral RNA replication (Zhu et al., 2005).uctures of HCV-JFH1, HCV-2b and 2b/JFH1 chimeric viruses. Intergenotypic homologous
clones were constructed that were joined between NS2-NS3 (JE39F), and within E2 at
RNA-transfected Huh7.5.1 cells were plated onto 22 mm-round micro cover glasses.
ibody(green) and DAPI(blue). C. Time courses of 2b/JFH1- and JFH1-transfected cells.
HCV core levels of culture ﬂuids were sampled at the time points indicated and core
dependently. Panel C shows representative date. D. Immunocytochemistry of HCV core.
ore antigen were plated onto 22 mm-round micro cover glasses. Immunocytochemistry
. Numbers at the bottom denote percentages of HCV core-positive cells. E. Time courses
infect naïve Huh7.5.1 cells in 60 mm-diameter plates at density of 3×105 cells per plate.
ours, 72 hours and 144 hours after inoculation. The experiment was done three times
n JFH1 and JEC3F supernatant HCV-RNA titer and core antigen. Four days after JFH1 and
antigen assay and realtime RT-PCR of HCV-RNA. Assays were done in triplicate and the
Fig. 3. Induction by interferon of the interferon-inducible genes, MxA (panel A), 25-OAS (panel B) and phosphorylated STAT1 (panel C) and STAT2 (panel D). JEC3F and JFH1 10 μg
RNA was transfected into Huh7.5.1 cells. Forty-eight hours after transfection, the cells were treated with 25 U/ml IFN-alpha 2b. Total cellular RNA was isolated before and 8 and
24 hours after IFN treatment. Relative gene expression levels of MxA (panel A) and 25-OAS (panel B) were determined by real-time PCR at the time points indicated. JEC3F and JFH1
RNA and MOCK was transfected into Huh7.5.1 cells. Forty eight hours after transfection, the cells were treated with 25 U/ml IFN-alpha 2b. Total cellular protein was isolated before
and 15 minutes after IFN treatment. Ten μg of extracted protein were used for analysis of phosphorylated STAT1, STAT2 protein and STAT1, STAT2 protein as controls. Assays were
done in triplicate and the data are shown as mean±sd. Asterisks indicate p-values of less than 0.05.
Fig. 4. Expression of SOCS1 mRNA (panel A), SOCS3 mRNA (panel B). Forty-eight hours
after transfection of JEC3F, JFH1 10 μg RNA or mock transfection into Huh7.5.1 cells,
total RNA and total protein were isolated. Relative gene expression levels of SOCS1
(panel A) and SOCS3 (panel B) and were determined by real time PCR. Values are
shown as relative to those of uninfected Huh 751 cells. Assays were done in triplicate
and the data are shown as mean±sd. Asterisks indicate p-values of less than 0.05.
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pathways. The NS5A and E2 proteins interfere with the action of IFN
by inhibiting the activity of PKR (He and Katze, 2002; Taylor et al.,
1999). NS5A also induced expression of IL-8 and attenuated
expression of ISGs (Polyak et al., 2001). HCV core protein has been
reported to bind the STAT1-SH domain (Lin et al., 2006) or destabilize
STAT1 (Lin et al., 2005) to block IFN signaling. It also has been
reported that overexpression of core protein upregulated SOCS3
expression (Bode et al., 2003). In this study, we used full-length HCV
cell culture and found, for the ﬁrst time, that SOCS3 expression is
upregulated differently depending on the genetic sequences of HCV
strains and that these differences in SOCS3 expression are associated
with sensitivity to IFN. Moreover, overexpression and knock down of
SOCS3 expression were closely associated with the IFN sensitivity of
the HCV-infected cells. These results indicate that interferon-
resistance of HCV-infected cells is directed by overexpression of
SOCS3, which may be upregulated by HCV proteins as reported (Bode
et al., 2003) (Kawaguchi et al., 2004). A sequence comparison of our
HCV2b and JFH1 clones has found 16 amino acid differences. These
structural differences of the core protein might affect cellular
responses to interferon (see the Supplementary Fig. 4).
It has been reported that IL-6 is the principal activator of STAT3 in
hepatocytes throughbinding its receptor (Hanadaet al., 2003; Ramadori
and Christ, 1999). Furthermore, plasma IL-6 levels are elevated in
Fig. 5. Differences in sensitivities to IFN between SOCS3-knock down, HCV transfected cells. JFH1 or JEC3F 10 μg RNA, and 80 pmol siRNA SOCS3-HSS113312 or MOCK were
electroporated into 5×106 uninfected Huh7.5.1 cells. A. Expression of SOCS3 mRNA in uninfected and HCV-infected Huh7 cells. Forty-eight hours after transfection, total RNA was
isolated. Relative gene expression level of SOCS3 were determined by real time PCR. Values are shown as relative to those of JFH1 infected Huh 751 cells. Assays were done in
triplicate and the data are shown as mean±sd. Asterisks indicate p-values of less than 0.05. B. Dose-dependent suppression of HCV replication by IFN in SOCS3-knock-down, HCV-
infected cells. The above siRNA and HCV RNA-transfected cells were divided into 12 wells. Forty eight hours after transfection, the cells were treated with 0, 1, 5 and 25 U/ml of IFN-
alpha 2b. Seventy two hours after treatment, quantiﬁcation of HCV core antigen in culture ﬂuids was carried out. Assays were done in triplicate and the data are shown as mean±sd.
Asterisks indicate p-values of less than 0.05.
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those reports, we found that IL-6 strongly induced SOCS3 expression in
Huh7.5.1 cells (Fig. 6C). More importantly, cellular IL6 expression levels
were in the order of uninfectedb JEC3Fbb JFH1-infected cells, which
correlated well with SOCS3 expression (Fig. 4) and with cellular
responses to IFN(Fig. 2). In addition, the IFN-resistant JcoreC3F, inwhich
the core region of JEC3F had been re-substituted by the JFH1-core,
induced comparatively higher levels of IL-6 and SOCS3 mRNA to JFH1
(Fig. 7). Taken together, our results indicate that the amino acid
sequence of the core protein determines IL-6 and SOCS3 expression
levels and, as a consequence, resistance to IFNs.
It remains to be clariﬁed what are the inducers of IL-6. There are
reports that HCV core protein activates toll-like receptor (TLR)-2 in
Huh7 cells and in adult human hepatocytes (Hoffmann et al., 2009;
Mozer-Lisewska et al., 2005). TLRs are known to activate downward
NF-kappaB signaling that upregulates IL-6 expression. Alternatively,
IL-6 may be secreted in response to cellular steatosis and insulin
resistance. HCV patients with obesity or insulin resistance are
refractory to IFN treatments. Such patients have higher levels of
hepatic SOCS3 expression than those without obesity or insulin
resistance (Miyaaki et al., 2009; Walsh et al., 2006). More recently,
Sabio, et al have reported that fatty acid-induced secretion of IL-6 from
adipocytes upregulates hepatic SOCS3, leading to insulin-resistance
(Sabio et al., 2008).
In conclusion, our study demonstrates that HCV intragenotypic
and inter-strain differences in IFN sensitivity can be, in most part,
attributable to the amino acid sequence of the HCV core protein and
that such IFN sensitivities are determined by cellular expression levels
of SOCS3 and IL-6. Therapeutic targeting of IL-6 potentially may be a
key to targeting IFN-resistance and improving antiviral chemother-
apeutics against HCV.Materials and Methods
Reagents and antibodies
Recombinant human interferon alpha-2b was from Schering-
Plough (Kenilworth, NJ). Anti-CD 81 antibody (JS-81)was from BD
Biosciences (Franklin Lakes, NJ) (Morikawa et al., 2007), anti-IL6
receptor antibody was from Chugai pharmaceutical Co (Tokyo, Japan),
anti-SOCS3 was from Cell Signaling (Beverly, MA), and anti-IL6
antibody was from R&D Systems (Minneapolis, MN).Cloning of HCV cDNA from patient serum
A serum sample was obtained from a 32- year-old male who
developed acute hepatitis after intravenous drug injection. Serum was
obtained one week after the onset of symptoms. Total RNA was
extracted from 150 μl of serum using ISOGEN (Nippon Gene, Osaka,
Japan). cDNAwas synthesizedusing SuperScript II (Invitrogen, Carlsbad,
CA) reverse transcriptase. PCR primers, based on a genotype 2b
prototype sequence, HC-J8 (accession number: D10988), were used to
amplify 14 fragments of HCV cDNA covering nt. 13-9478 (nucleotide
numbers corresponded to HC-J8) by PCR. All amplicons were puriﬁed
and cloned into the pGEM-T EASY vector (Promega, Madison, WI) and
nucleotide sequences were determined using Big Dye Terminator Cycle
Sequencing Ready Reaction kits (Applied Biosystems, Foster City, CA)
and an automated DNA sequencer (ABI PRISM® 310 Genetic Analyzer;
Applied Biosystems). The consensus sequence of ﬁve clones was
adopted for each region. Each consensus sequence segment of HCV
was assembled into pJFH1-full (Wakita et al., 2005) by substituting the
insert sequence of pJFH1-full.
Fig. 6. IL-6 expression in HCV infected cells and change in IFN sensitivity by treatment with anti-IL6 antibody. A. Expression of cytoplasmic phospho-STAT3 in uninfected and HCV-
infected Huh7 cells. JEC3F, JFH1 10 μg RNA and MOCK was transfected into Huh7.5.1 cells. Forty eight hours total cellular protein was isolated. Ten μg of extracted protein were used
for analysis of phosphorylated STAT3, STAT protein and β-actin as controls. B. Expression of Interleukin-6 mRNA in uninfected and HCV-infected Huh7 cells. Forty-eight hours after
transfection, total RNAwas isolated. Relative gene expression level of IL6 were determined by real time PCR. Values are shown as relative to those of uninfected Huh 751 cells. Assays
were done in triplicate and the data are shown as mean±sd. C. IL-6 induces SOCS3 strongly in uninfected Huh7.5.1 cells. Uninfected Huh7.5.1 cells were treated with 10 ng/ml
recombinant human IL6 (PEPRO TEC EC, London, England). Fifteen minuets after treatment, total RNA was isolated. Relative gene expression levels of SOCS1 and SOCS3 were
determined by real time PCR. Uninfected Huh7.5.1 cells that were not treated with IL6 were used as a control. Values are shown as relative to those of uninfected Huh 751 cells.
Assays were done in triplicate and the data are shown is mean±sd. D. Dose-dependent suppression of HCV replication by IFN in HCV-infected cells pre-treated with anti-IL-6
antibody. Immediately after electroporation, HCV RNA-transfected cells were divided into 12 wells and pretreated with 1 μg/ml anti-IL6 antibody. Forty eight hours after
transfection, the cells were washed with PBS and treated with 0, 1, 5 and 25 U/ml of IFN-alpha 2b. Seventy two hours after treatment, quantiﬁcation of HCV core antigen was carried
out in culture ﬂuids. Assays were done in triplicate and the data are shown as mean±sd. E. Core protein secretion levels following treatment of HCV-transfected cells with anti-IL-6
antibody. After treatment with anti-IL-6 antibody, HCV RNA-transfected cells were divided into 12 wells. Five days after transfection, quantiﬁcation of HCV core antigen was carried
out in culture ﬂuids. Assays were done in triplicate and the data are shown as mean±sd. F. Expression of SOCS3 mRNA in uninfected and HCV-infected Huh7 cells. Forty-eight hours
after transfection, total RNA was isolated. Relative SOCS3 gene to beta-actin gene expression were determined by real time PCR. Values are shown as relative to those of uninfected
Huh 751 cells. Assays were done in triplicate and the data are shown as mean±sd. Asterisks indicate p-values of less than 0.05.
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transfection
Chimeric HCV constructs of HCV-2b and JFH1 were shown in
Figs. 1A and 7A. To construct 2b/JFH1-based intragenotypic chimera,
JE31F, the 2b sequence of core through E2 (nt. 342- 2541)was fused to
the EcoRI-JFH1- 5′-untranslated region (UTR) DNA by fusion PCR. The
fused 5′UTR-E2 fragment and JFH1-E2-NS3 (nt2541 through 5324)
were assembled by fusion PCR and cloned into pGEM-T EASY. The
product was digested by EcoRI and AfeI and insert into pJFH1.
Plasmids pJE39F, pJEC3F, pJcoreC3F and p2bcore JFH1 were con-
structed using a similar procedure. Plasmids pJEC3F and pJE39F were
joined between NS2 and NS3, andwithin NS2 at nt. 2867, respectively.
Plasmid pJcoreC3F was made by substitution of the core region of 2b/
JFH1 with that of JFH1. The plasmid p2bcoreJFH1 was made by
substitution of the core region of JFH1 with that of 2b/JFH1.
Cells and cell culture
Huh7.5.1 cells were maintained in Dulbecco's modiﬁed minimal
essential medium (Sigma, St. Louis, MO) supplemented with 10% fetal
calf serum at 37 °C under 5% CO2.
HCV cell culture system
Full-length HCV expression plasmids were as follows: pJFH1-full
(Wakita et al., 2005), pJE31F, pJE39F, pJEC3F, pJcoreC3F, p2bcoreJFH1,
and pFL-H77/JFH1, pFL-J6/JFH1 (Lindenbach et al., 2005). These
plasmids were linearized at their 3′ ends and used as templates for
HCV RNA synthesis using the RiboMax Large Scale RNA Production
System (Promega, Madison, WI). After DNase I (RQ-1, RNase-free
DNase, Promega) treatment, the HCV RNA was puriﬁed using ISOGEN
(Nippon Gene, Tokyo, Japan). For the RNA transfection, Huh7.5.1 cells
were washed twice with PBS, and 5×106 cells were suspended in
Opti-MEM I (Invitrogen Carlsbad, CA) containing 10 μg of HCV RNA,
transferred into a 4 mm electroporation cuvette and ﬁnally subjected
to an electric pulse (1,050 μF and 270 V) using the Easy Jet system
(EquiBio, Middlesex, UK). After electroporation, the cell suspensionwas left for 5 min at room temperature and then incubated under
normal culture conditions in a cell culture dish.
Quantiﬁcation of HCV core antigen in culture supernatants
Culture supernatants of HCV RNA transfected Huh7.5.1 cells were
collected on the days indicated, passed through a 0.45 μm ﬁlter
(MILLEX-HA, Millipore, Bedford, MA) and stored at -80 °C. The
concentrations of core antigen in the culture supernatants were
measured using a chemiluminescence enzyme immunoassay (CLEIA)
according to the manufacturer's protocol (Lumipulse Ortho HCV
Antigen, Ortho-Clinical Diagnostics, Tokyo, Japan).
Re-infection analyses
Titer-adjusted supernatants (including 0.03 fmol HCV core
antigen) from HCV RNA-transfected cells were inoculated onto
naïve Huh7.5.1 cells plated on a 6 cm plate at a density of 3×105
cells per plate. Forty-eight hours after inoculation, anti-core immu-
nostaining was carried out with mouse anti-HCV core protein
monoclonal antibody and the numbers of infected cells were counted.
HCV core antigen in culture supernatants was measured at 24 hours,
48 hours, 72 hours and 144 hours after inoculation.
Real-time RT-PCR analysis
For the detection of HCV RNA in culture supernatant, supernatant
was passed through a 0.45 μm ﬁlter (MILLEX-HA, Millipore, Bedford,
MA) and stored at -80 °C until use. Protocol and primers for the
realtime RT-PCR analysis of HCV-RNA has been described previously
(Sekine-Osajima et al., 2008). For the detection of endogenous
mRNAs, total cellular RNA was isolated using ISOGEN (Nippon
Gene). Two micrograms of total cellular RNA were used to generate
cDNA from each sample using SuperScript II. Expression of mRNAwas
quantiﬁed using the TaqMan Universal PCR Master Mix and the ABI
7500 Real-Time PCR System (Applied Biosystems, Foster City CA).
Some primers have been described (Sekine-Osajima et al., 2008).
SOCS3; forward, 5′-CAC ATG GCA CAA GCA CAA GAA G-3′ and reverse,
Fig. 7. Replacement of the HCV-2b-core region with JFH1-core causes upregulation of SOCS3 and IL-6 and restores resistance to IFN. A. Genome maps of JFH-1, JEC3F , J core C3F, 2b
core JFH1 recombinant cDNA. J core C3 Fwasmade by substitution of the core region of 2b/JFH1with that of JFH1. The 2b core JFHwasmade by substitution of the core region of JFH1
with that of 2b/JFH1. B. Comparison of IFN-alpha sensitivity among JFH1 and JEC3F and core region substitution chimeric viruses. Ten μg of J core C3F, 2b core JFH1, JEC3F, JFH1 RNA
were transfected into 5×106 Huh7.5.1 cells and were divided into 12 wells. Forty eight hours after transfection, the cells were treated with 0, 1, 5 and 25 U/ml of IFN-alpha 2b.
Seventy two hours after treatment, quantiﬁcation of HCV core antigen was carried out in culture ﬂuids. Assays were done in triplicate and the data are shown as mean±sd. Asterisks
indicate p-values of less than 0.05. C, D. Core substitution leads to SOCS3 and IL-6 mRNA over-expression. Forty eight hours after transfection into cells, total RNA was isolated.
Relative gene expression level SOCS3 (panel C) and IL6 (panel D) were determined by real time PCR. Values are shown as relative to those of uninfected Huh 751 cells. Assays were
done in triplicate and the data are shown as mean±sd. Asterisks indicate p-values of less than 0.05. E. Change of secretion of core protein following core protein substitution. HCV
RNA-transfected cells were divided into 12 wells. Five days after transfection, quantiﬁcation of HCV core antigen was carried out in culture ﬂuids. Assays were done in triplicate and
the data are shown as mean±sd. Asterisks indicate p-values of less than 0.05.
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89G. Suda et al. / Virology 407 (2010) 80–905′-GGA GAA GCT GGA GAC TCA GGT G-3′, SOCS1; forward, 5′-CAC TTC
CGC ACA TTC CGT TCG-3′ and reverse, 5′-GAG GCC ATC TTC ACG CTA
AGG-3′, IL6; forward, 5´-GGT ACA TCC TCG ACG GCA TCT-3′ and
reverse, 5′-GTG CCT CTT TGC TGC TTT CAC-3′, 25OAS; forward, 5´- CCA
CCT TGG AAA GTG CCG ACA ATG CAG ACA-3′ and reverse, 5′-CGA GTC
TTT AAA AGC GAT TGC CAG ATG ATC -3′, MxA; forward, 5´-GCC AGC
AGC TTC AGA AGG CCA TGC TGC AGC -3′ and reverse, 5′-GGG CAAGCC
GGC GCC GAG CCT GCG TCA GCC -3′.
The siRNAs
The siRNAs directed against SOCS3 were designed as follows:
SOCS3-HSS113312 stealth (sequence 5′- CCC AGA AGA GCC UAU UAC
AUC UAC U-3 ′and 5′-AGU AGA UGU AAU AGG CUC UUC UGG G-3′,
Invitrogen) was used. 10 μg in vitro-synthesized HCV-RNA and 80
pmol siRNA SOCS3-HSS113312 or MOCK or control siRNA (negative
universal control Med #2, Invitrogen) were electroporated into 5×10
naïve Huh7.5.1 cells using the protocol described in HCV cell culture
system. Forty-eight hours after transfection, expression levels of
SOCS3 mRNA were measured by real-time PCR. The difference in IFN
sensitivity between SOCS3 knock down HCV infected cells and control
HCV infected cells was determined by measuring supernatants HCV
core antigen 72 hours after addition of IFN.
Immunohistochemistry for HCV core
HCV-JFH1 transfected or infected Huh7.5.1 cells were cultured on
22 mm-round micro cover glasses (Matsunami, Tokyo, Japan). For
detection of HCV core, cells were ﬁxed with cold acetone for 15 min.
The cells were incubated with the primary antibodies for 1 hour at
37 °C, and with Alexa Fluor 488 goat anti-mouse IgG antibody
(Molecular Probes, Eugene, OR) for 1 hour at room temperature.
Cells were mounted with VECTA SHIELD Mounting Medium and DAPI
(Vector Laboratories, Burlingame, CA) and visualized by ﬂuorescence
microscopy (BZ-8000, KEYENCE, Osaka, Japan).
Western blot analysis
Western blotting was performed as described (Tanabe et al.,
2004). Brieﬂy, 10 μg of total cell lysate was separated by SDS-PAGE,
and blotted onto a polyvinylidene ﬂuoride (PVDF) membrane. The
membrane was incubated with the primary antibodies followed by a
peroxidase-labeled anti IgG antibody, and was visualized by chemi-
luminescence using the ECL Western Blotting Analysis System
(Amersham Biosciences, Buckinghamshire, UK).
Statistical analyses
Statistical analyses were performed using Student's t-test; p-values
of less than 0.05 were considered statistically signiﬁcant.
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Appendix A. Supplementary data
Supplementary Fig. 1. Infectivity of the full-length 2b HCV RNA and
2b/JFH1 chimeric virus, JEC3F. A. Challenge of human liver-engrafted
albumin-uPA/SCID mice with culture ﬂuid from JFH1 and JEC3F cells.
Cell culture ﬂuids from the JFH1 clone and JEC3F were injectedintravenously into human liver engrafted albumin-uPA/SCID mice.
Serum samples were obtained from the mice every 2 weeks after
injection and the HCV RNA titer was determined. B. Fig. 1B Challenge
of human liver-engrafted albumin-uPA/SCID mice by intrahepatic
injection of in vitro synthesized, full-length 2b HCV RNA. Five hundred
μl of RNA solution containing 30 μg of in vitro synthesized full-length
2b HCV RNAwas injected into the livers of anesthetized chimeric mice
through a small abdominal incision. Serum samples were obtained
from the mice every 2 weeks after injection and the HCV RNA titer
was determined.
Supplementary Fig. 2. Comparisons of replication efﬁciency of
JFH1and J6/JFH1, 2b/JFH1 chimeras after transfection into Huh7.5.1-
cells. A. Structures of theJ6/JFH1 and 2b/JFH1 genomes. J6 is joined
between NS2 and NS3 with JFH1. 2b-HCV is joined with JFH1within
NS2 at nt. 2867. B Measurements of core protein in cell culture ﬂuids.
Ten μg of JFH1, J6/JFH1, 2b/JFH1 RNA were transfected into 5×106
Huh7.5.1 cells and the cells were cultured in 100 mm-diameter plates.
The culture ﬂuids from JFH1, J6/JFH1, H77/JFH1or 2b/JFH1-trans-
fected Huh7.5.1 cells were collected separately on the days indicated
and the levels of core antigen were measured. These experiments
were done three times with similar results independently. Panel B
shows representative date.
Supplementary Fig. 3. Inhibition of infection by blocking CD81.
Huh 7.5.1 cells were plated into a 6 well plate at 1.4×105 cells per
well. After 48 hours, the cells were incubated with anti-CD81 or
isotypematched control antibody at the concentration indicated for 1
hour. Subsequently, cells were infected with 1 ml of JEC3F stock cell
culture ﬂuids at day 2 for 4 hours and washed with PBS. 48 hours after
inoculation, anti-core immunostaining was performed with mouse
anti-HCV core protein monoclonal antibody (Panels B and C).
Quantiﬁcation of HCV core antigen was carried out in culture ﬂuids
at 48 hours after infection (Panel A).
Supplementary Fig. 4. Comparison between 2b and JFH-1 core
amino acid sequence.
Note: Supplementary materials related to this article can be found
online at doi:10.1016/j.virol.2010.07.041.
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